122 related articles for article (PubMed ID: 2397113)
21. Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer: detection in ascitic fluid and localization to primary sites and metastatic implants.
Menzin AW; Loret de Mola JR; Bilker WB; Wheeler JE; Rubin SC; Feinberg RF
Cancer; 1998 Jan; 82(1):152-8. PubMed ID: 9428492
[TBL] [Abstract][Full Text] [Related]
22. Differentiation between metaplastic carcinomas and sarcomas of the human female breast by fibronectin.
Christensen L; Nielsen M; Hølund B; Clemmensen I
Virchows Arch A Pathol Anat Histopathol; 1985; 407(4):465-76. PubMed ID: 2996215
[TBL] [Abstract][Full Text] [Related]
23. Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast.
Yoshida T; Matsumoto E; Hanamura N; Kalembeyi I; Katsuta K; Ishihara A; Sakakura T
J Pathol; 1997 Aug; 182(4):421-8. PubMed ID: 9306963
[TBL] [Abstract][Full Text] [Related]
24. Cathepsin-D expression in breast lesion: an immunohistochemical study.
Brujan I; Mărgăritescu C; Simionescu C; Pirici D; Fronie A; Foarfă C; Stepan A; Vrabete M
Rom J Morphol Embryol; 2009; 50(1):31-9. PubMed ID: 19221643
[TBL] [Abstract][Full Text] [Related]
25. Immunocytochemical identification of cell types in benign and malignant breast diseases: variations in cell markers accompany the malignant state.
Rudland PS; Leinster SJ; Winstanley J; Green B; Atkinson M; Zakhour HD
J Histochem Cytochem; 1993 Apr; 41(4):543-53. PubMed ID: 8450194
[TBL] [Abstract][Full Text] [Related]
26. Connective tissue stromal changes in tumours and tumour-like lesions of the breast.
Pai MR; Pai KN; Rao RV; Naik R; Shankarnarayana ; Baliga P
Indian J Pathol Microbiol; 1999 Jul; 42(3):327-32. PubMed ID: 10862293
[TBL] [Abstract][Full Text] [Related]
27. The distribution of fibronectin, laminin and tetranectin in human breast cancer with special attention to the extracellular matrix.
Christensen L
APMIS Suppl; 1992; 26():1-39. PubMed ID: 1576006
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical study of D5 antigen (an oestrogen receptor related protein) in normal breast, benign breast disease, and mammary carcinoma in situ.
Girling A; Caleffi M; King RJ; Millis RR
J Clin Pathol; 1988 Apr; 41(4):448-53. PubMed ID: 2835402
[TBL] [Abstract][Full Text] [Related]
29. P-cadherin as a marker in the differential diagnosis of breast lesions.
Kovács A; Walker RA
J Clin Pathol; 2003 Feb; 56(2):139-41. PubMed ID: 12560394
[TBL] [Abstract][Full Text] [Related]
30. Cancerization of small ectatic ducts of the breast by ductal carcinoma in situ cells with apocrine snouts: a lesion associated with tubular carcinoma.
Goldstein NS; O'Malley BA
Am J Clin Pathol; 1997 May; 107(5):561-6. PubMed ID: 9128269
[TBL] [Abstract][Full Text] [Related]
31. Fibronectin in differential diagnosis of primary hepatomas and carcinoma metastases in the liver.
Szendröi M; Lapis K
Acta Morphol Hung; 1985; 33(1-2):101-9. PubMed ID: 3012968
[TBL] [Abstract][Full Text] [Related]
32. Nuclear morphometry of benign and malignant breast lesions.
Skjørten F; Kaaresen R; Jacobsen U; Skaane P; Amlie E
Eur J Surg Oncol; 1991 Aug; 17(4):350-3. PubMed ID: 1874292
[TBL] [Abstract][Full Text] [Related]
33. There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions.
Chauhan H; Abraham A; Phillips JR; Pringle JH; Walker RA; Jones JL
J Clin Pathol; 2003 Apr; 56(4):271-6. PubMed ID: 12663638
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic analysis of breast lesions associated with multiple papillomas.
Ali-Fehmi R; Carolin K; Wallis T; Visscher DW
Hum Pathol; 2003 Mar; 34(3):234-9. PubMed ID: 12673557
[TBL] [Abstract][Full Text] [Related]
35. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
[TBL] [Abstract][Full Text] [Related]
36. Localization of mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase type II in human breast and its disorders.
Sasano H; Frost AR; Saitoh R; Matsunaga G; Nagura H; Krozowski ZS; Silverberg SG
Anticancer Res; 1997; 17(3C):2001-7. PubMed ID: 9216657
[TBL] [Abstract][Full Text] [Related]
37. Argyrophilic cells in carcinoma of the female breast.
Partanen S; Syrjänen K
Virchows Arch A Pathol Anat Histol; 1981; 391(1):45-51. PubMed ID: 6169189
[TBL] [Abstract][Full Text] [Related]
38. The histopathology of non-palpable breast lesions detected by clinical mammography.
Skjørten FJ; Skaane P; Jacobsen U; Kaaresen R; Haaheim LL
Eur J Surg Oncol; 1990 Dec; 16(6):475-80. PubMed ID: 2253791
[TBL] [Abstract][Full Text] [Related]
39. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability.
Kleer CG; van Golen KL; Zhang Y; Wu ZF; Rubin MA; Merajver SD
Am J Pathol; 2002 Feb; 160(2):579-84. PubMed ID: 11839578
[TBL] [Abstract][Full Text] [Related]
40. [Morphology, topography and growth pattern of benign proliferative breast lesions and pre-invasive cancers].
Böcker W; Jarasch ED; Nagle EB; Höhne R
Verh Dtsch Ges Pathol; 1985; 69():96-107. PubMed ID: 3006396
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
